A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Annals of Oncology

Volumn 18, Issue 9, 2007, Pages 1529-1538

  Candelaria, M ^b   Gallardo Rincon D ^b   Arce, C ^b   Cetina, L ^b   Aguilar Ponce, J L ^b   Arrieta, O ^b   Gonzalez Fierro A ^a   Chavez Blanco A ^a   de la Cruz Hernandez E ^a   Camargo, M F ^a   Trejo Becerril, C ^a   Perez Cardenas E ^a   Perez Plasencia C ^a   Taja Chayeb, L ^a   Wegman Ostrosky, T ^b   Revilla Vazquez, A ^a   Dueñas González, Alfonso ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Epigenetic therapy; Hydralazine; Magnesium valproate; Phase II; Refractory; Solid tumors

Indexed keywords

ANASTROZOLE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GROWTH FACTOR; HISTONE DEACETYLASE; HYDRALAZINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; SULFADIMIDINE; TAMOXIFEN; TOPOTECAN; VALPROATE MAGNESIUM; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DELIRIUM; DERMATITIS; DIARRHEA; DIZZINESS; DNA METHYLATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RECHALLENGE; DRUG RESPONSE; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EDEMA; ENZYME ACTIVITY; EPIGENETICS; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HYPOALBUMINEMIA; INFECTION; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CARCINOMA; PATIENT SELECTION; PELVIS PAIN SYNDROME; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; SIDE EFFECT; SINGLE DRUG DOSE; SLOW DRUG RELEASE; SOLID TUMOR; TESTIS CARCINOMA; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREMOR; UTERINE CERVIX CARCINOMA; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASES; HUMANS; HYDRALAZINE; MALE; NEOPLASMS; VALPROIC ACID;

EID: 34548395116     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm204     Document Type: Article

References (42)

1. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94: 1087-1092.
2. Pérez-Plasencia C, Dueñas-González A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer 2006; 5: 27.
3. Cornacchia E, Golbus J, Maybaum J et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988; 140: 1197-2000.
4. Segura-Pacheco B, Trejo-Becerril C, Pérez-Cárdenas E et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003; 9: 1596-1603.
5. Chuang JC, Yoo CB, Kwan JM et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′ -deoxycytidine. Mol Cancer Ther 2005; 4: 1515-1520.
6. Angeles E, Vázquez-Valadez VH, Vázquez-Valadez O et al. Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase. Lett Drug Design Discov 2005; 4: 282-286.
7. Arce C, Candelaria M, Segura-Pacheco B et al. Hydralazine target: From blood vessels to the epigenoma. J Transl Med 2006; 4: 10.
8. Deng C, Lu O, Zhang Z et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48: 746-756.
9. Zambrano P, Segura-Pacheco B, Pérez-Cárdenas E et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005; 5: 44.
10. Arce C, Pérez-Plasencia C, González-Fierro A et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant Doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 2006; 1: E98.
11. Phiel CJ, Zhang F, Huang EY et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizzer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
12. Kramer OH, Zhu P, Ostendorff HP et al. The histone deacelylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003; 22: 3411-3420.
13. Chávez-Blanco A, Segura-Pacheco B, Pérez-Cárdenas E et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005; 4: 22.
14. Bug G, Ritter M, Wassmann B et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104: 2717-2725.
15. García-Manero G, Kantarjian M, Sánchez-González B et al. Phase 1/2 study of the combination of 5-aza-2′ -deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.
16. Lyon CM, Linge DK et al. DNA demethylating agents and a PPA-γ agonist cooperate to induce apoptosis in lung cancer cell lines. Proc Am Assoc Cancer Res 2006: 47 Abstract 41.
17. Chávez-Blanco A, Pérez-Plasencia C, Pérez-Cárdenas E et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006; 6: 2.
18. Segura-Pacheco B, Pérez-Cárdenas E, Taja-Chayeb L et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med 2006; 4: 32.
19. Castañeda-Hernández G, Falcon-Neri A, Herrere-Abarca A et al. Determination of three acetylator phenotypes in a Mexican population using sulfamethazine metabolic ratio. Am J Ther 1995; 2: 57-60.
20. Guppy AE, Rusfin GJ. CA125 response: Can it replace the traditional response criteria in ovarian cancer? Oncologist 2002; 7: 437-443.
21. Sandoval Guerrero K, Revilla Vázquez A, Segura-Pacheco B et al. Determination of 5-methyl-cytosine and cylosine in tumor DNA samples of cancer patients. Electrophoresis 2005; 26: 1057-1062.
22. Reece PA, Gozamanis I, Zacest R. Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man. J Chromatogr 1980; 181: 427-440.
23. Nyce J, Liu L, Jones PA. Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acids Res 1986; 14: 4353-4367.
24. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989; 49: 5829-5836.
25. Bredberg A, Bodmer W. Cytostatic drug treatment causes seeding of gene promoter methylation. Eur J Cancer 2007; 43: 947-954.
26. Wang C, Mirkin BL, Dwivedi RS. DNA (cytosine) methyltransferase overexpression is associated with acquired drug resistance of murine neuroblastoma cells. Int J Oncol 2001; 18: 323-329.
27. Qui YY, Mirkin BL, Dwivedi RS. Inhibition of DNA methyltranslerase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev 2005; 29: 456-463.
28. Ozdag H, Teschendorff AE, Ahmed AA et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006; 7: 90.
29. Fuks F, Burgers WA, Brehm A et al. DNA methyttransferase Dnmtl associates with histone deacetylase activity. Nat Genet 2000; 24: 88-91.
30. Cameron EE, Bachman KE, Myohanen S et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
31. Li L, Shi H, Yiannoutsos C et al. Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. J Comput Biol 2005; 12: 370-390.
32. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: Current views and new therapeutic prospective. J Cell Physiol 2006; 207: 571-581.
33. Sebastiani V, Ricci F, Rubio-Viquiera B et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in-pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 2006; 12: 2492-2497.
34. Buermeyer AB, Wilson-Van Patten C, Baker SM et al. The human MLH1 cDNA complements DNA mismatch repair defects in MIh1 -deficient mouse embryonic fibroblasts. Cancer Res 1999; 59: 538-541.
35. Asano T, Nakamura K, Fujii H et al. Altered expression of topoisomerase II alpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation. Br J Cancer 2005; 92: 1486-1492.
36. Samiowski WE, Leachman SA, Wade M, Cassidy P et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23: 3897-3905.
37. Fischer JR, Ohnmacht U, Rieger N et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006; 54: 109-116.
38. Grady WM, Rajput A, Lutterbaugh JD et al. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61: 900-902.
39. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-65.
40. Bourg V, Lebrun C, Chichmanian FM et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity. Ann Oncol 2001; 12: 217-219.
41. Gronlund B, Hansen HH, Hogdall C et al. Do CA125 response criteria overestimate tumour response in second-line treatment of epithellal ovarian carcinoma? Br J Cancer 2004; 90: 377-382.
42. Gronlund B, Hogdall C, Hilden J et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004; 22: 4051-4058.